ZLD 1039

Discontinued Product

5847 has been discontinued.

View all EZH2 products.
说明: Potent and selective EZH2 inhibitor; orally bioavailable
化学名: 3-[Ethyl(tetrahydro-2H-pyran-4-yl)amino]-N-[(2,3,5,6,7,8-hexahydro-1-methyl-3-oxo-4-isoquinolinyl)methyl]-2-methyl-5-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]benzamide
纯度: ≥98% (HPLC)
说明书
引用文献
评论
文献 (5)

生物活性 for ZLD 1039

ZLD 1039 is a potent and selective EZH2 inhibitor (IC50 = 5.6 nM). Displays selectivity for EZH2 over a panel of HMTs (inhibition less than 30% at 16 μM). Blocks H3K27 methylation in breast cancer cell lines. Induces tumor regression and metastasis in breast cancer xenograft-bearing mice. Reactivates silenced tumor suppressors in vivo. Orally bioavailable.

技术数据 for ZLD 1039

分子量 612.8
公式 C36H48N6O3
储存 Store at -20°C
纯度 ≥98% (HPLC)
CAS Number 1826865-46-6
PubChem ID 132517142
InChI Key SZAYCVHJDOWSNY-UHFFFAOYSA-N
Smiles CCN(C1=CC(C2=CN=C(N3CCN(CC3)C)C=C2)=CC(C(NCC4=C5CCCCC5=C(NC4=O)C)=O)=C1C)C6CCOCC6

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

参考文献 for ZLD 1039

参考文献是支持产品生物活性的出版物。

Song et al (2016) Corrigendum: Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer. Sci.Rep. 29 24893 PMID: 27128979

按产品操作查看相关产品

查看全部 EZH2 Inhibitors

关键词: ZLD 1039, ZLD 1039 supplier, ZLD1039, Potent, selective, EZH2, inhibitors, inhibits, orally, bioavailable, H3K27, methylation, 5847, Tocris Bioscience

篇 ZLD 1039 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 ZLD 1039 的引用文献。

ZLD 1039 的评论

目前没有该产品的评论。 Be the first to review ZLD 1039 and earn rewards!

Have you used ZLD 1039?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Stem Cells Scientific Review

Stem Cells Scientific Review

Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.

Cancer Metabolism Poster

Cancer Metabolism Poster

This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.

Stem Cells Poster

Stem Cells Poster

Written by Rebecca Quelch and Stefan Przyborski from Durham University (UK), this poster describes the isolation of pluripotent stem cells, their maintenance in culture, differentiation, and the generation and potential uses of organoids.